The American company Arcturus has signed an agreement with the Israel to supply vaccines against corona

The American pharmaceutical company Arcturus has signed an agreement with the Israeli Ministry of Health to supply vaccines against corona, according to an announcement published on Thursday night.
The full terms of the deal and its scope have not been published. According to the company's announcement abroad, this is a binding agreement in principle, but its final details will be agreed within 30 days. Israel will have the right to keep and store vaccine doses for its citizens. Such an agreement with Arcturus, after Singapore, joins an agreement signed with the American modern company, and according to reports, Israel is also in contact with AstraZeneca, which is in an advanced stage of vaccine trials developed at Oxford University.
Arcturus is a pharmaceutical company from San Diego, California, which develops RNA-based drugs. It is a relatively small company with 90 employees, established in 2013 and currently traded at a value of $ 1.1 billion on the Nasdaq. It has an Israeli connection: in 2017 it merged with the Israeli pharmaceutical company Alcobra.
It has several drugs in development, four of which are in the developmental and experimental trials (before trials in humans) and one drug which is in clinical trials 1 (safety trials). And a number of developments in collaboration with other companies. However, Arcturus does not currently have a product, drug or vaccine that is already on the market. And of course she has no experience in producing and distributing vaccines on a large scale.